Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Recent & Breaking News (NDAQ:IMNN)

Celsion Corporation to Hold Second Quarter 2014 Financial Results

PR Newswire July 31, 2014

Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer

PR Newswire July 28, 2014

Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer

PR Newswire July 24, 2014

Celsion Corporation Announces $1 Million NIH, NIBIB - Career Development Award Grant for Glioblastoma Research with ThermoDox® and HIFU

PR Newswire July 21, 2014

Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell

GlobeNewswire July 15, 2014

Celsion Corporation Announces Commercialization of Reagent Products

PR Newswire July 15, 2014

Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014

PR Newswire July 14, 2014

Celsion Corporation Completes Acquisition of EGEN, Inc.

PR Newswire June 20, 2014

Celsion Closes Second $5 Million Tranche under Loan Facility Agreement with Hercules Technology Growth Capital

PR Newswire June 10, 2014

Celsion Corporation to Acquire EGEN, Inc.

PR Newswire June 10, 2014

Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

PR Newswire May 21, 2014

Celsion Corporation Announces ThermoDox® Abstract Accepted at the 2014 American Society of Clinical Oncology 50th Annual Meeting

PR Newswire May 16, 2014

Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update

PR Newswire May 8, 2014

Celsion Corporation to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014

PR Newswire May 1, 2014

Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox® in Primary Liver Cancer Presented at ECIO 2014

PR Newswire April 24, 2014

Celsion Announces ThermoDox® HCC Program to be discussed at the 2014 European Conference on Interventional Oncology in Berlin, Germany

PR Newswire April 10, 2014

Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound

PR Newswire April 9, 2014

Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update

PR Newswire March 13, 2014

Celsion Corporation to Hold Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014

PR Newswire March 6, 2014

Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer

PR Newswire February 27, 2014